# Narration and storyboard draft: Injectable Peptide Stacks and Human Recovery

Authored draft, approximately 60–90 seconds; no rendered video claimed.

Injectable peptide stacks are often promoted for recovery, but the exact claim matters. CJC-1295 and ipamorelin have human evidence that they stimulate growth hormone. That is a real pharmacological effect. It does not establish that their combination restores physical function or accelerates healing in adults without diagnosed hormone deficiency. Our HSEF v5.3 review examined more than fifty original reports, mostly component, mechanism and comparator studies. Selected GH-axis treatments improved function in specific clinical settings. Other trials increased hormones or lean mass without improving strength or function, and metabolic risks required monitoring. A recent rat study of a different BPC-157 and TB-500 combination found no extra benefit over individual components. We therefore assign the exact CJC-ipamorelin recovery claim Gamma, with moderate confidence: plausible biology, incomplete clinical causal support. Consensus helped identify evidence and research gaps; the source claims were checked against originals. The next decisive step is a formulation-verified, blinded clinical comparison with component arms, a meaningful functional endpoint and a benefit-harm assessment. Hormone levels should be secondary, not a substitute for recovery.

1. Show the exact claim, grade and confidence.
2. Show selected publication milestones; label experimental systems and clinical endpoints.
3. Contrast the strongest result with its source-specific limitation.
4. End with the boundary experiment and primary-source links.

Use authored schematics; do not depict Consensus meters as causal confidence or reproduce publisher graphics without appropriate permission.